The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent Helicobacter pylori Infection: A Meta-Analysis. CME
Open accessAbstract
BACKGROUND: Levofloxacin-based triple therapy has been suggested as an alternative salvage therapy to bismuth-based quadruple therapy for persistent Helicobacter pylori (H. pylori) infection. METHODS: A search of PUBMED, EMBASE, EBM Review databases and abstracts from recent Digestive Disease Week, United European Gastroenterology Week, and European Helicobacter Study Group conferences was performed. Randomized controlled trials (RCTs) comparing levofloxacin-based triple salvage therapy (levofloxacin + amoxicillin + PPI) to bismuth-based quadruple salvage therapy (bismuth + tetracycline + metronidazole + PPI) were selected for meta-analysis. Additionally, all prospective trials evaluating this levofloxacin-based triple therapy as salvage therapy were pooled to analyze optimal levofloxacin treatment duration and dosing. All selected trials confirmed prior treatment failure and post-salvage treatment eradication. RESULTS: Four RCTs compared a 10-day regimen of levofloxacin-based triple therapy to 7-day bismuth-based quadruple therapy (n = 391 patients). Levofloxacin-based triple therapy was superior to quadruple therapy (RR = 1.41 [95% CI: 1.25-1.59]). Levofloxacin-based triple therapy was better tolerated than quadruple therapy with a lower incidence of side effects (RR = 0.51 [95% CI: 0.34-0.75]) and side effects prompting discontinuation of therapy (RR = 0.30 [95% CI: 0.10-0.89]). Eleven trials (n = 547 patients) evaluating levofloxacin-based triple therapy demonstrated higher eradication rates with 10-day versus 7-day regimen (87%[95% CI: 82%-92%]vs 68%[95% CI: 62%-74%]) yet eight trials (n = 477 patients) demonstrated no difference with 500 mg daily versus 250 mg b.i.d. dosing of levofloxacin (81%[95% CI: 78%-89%]vs 84%[95% CI: 66%-97%]). CONCLUSIONS: A 10-day course levofloxacin triple therapy is more effective and better tolerated than 7-day bismuth-based quadruple therapy in the treatment of persistent H. pylori infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,465
Helicobacter pylori Infection and Gastric Lymphoma
Parsonnet, J., Hansen, S., Rodriguez, L., Gelb, A. B., Warnke, R. A., Jellum, E., Orentreich, N., Vogelman, J. H., & Friedman, G. D. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301803 · Cited by 1,831
Malfertheiner, P., Mégraud, F., O'Morain, C., Hungin, A. P. S., Jones, R., Axon, A., Graham, D. Y., Tytgat, G., & The European Helicobacter Pylori Study Group (EHPSG) (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01169.x · Cited by 1,237
H pylori antibiotic resistance: prevalence, importance, and advances in testing
Mégraud, F. (2004) · Gut · doi:10.1136/gut.2003.022111 · Cited by 955
Factors influencing the eradication of Helicobacter pylori with triple therapy
Graham, D. Y., Lew, G. M., Malaty, H. M., Evans, D. G., Evans, D. J., Klein, P. D., Alpert, L. C., & Genta, R. M. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90095-g · Cited by 545
Houben, Beek, D. V. D., Hensen, Craen, A. J. M. D., Rauws, & Tytgat (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00555.x · Cited by 333
Meyer, J. M., Silliman, N. P., Wang, W., Siepman, N. Y., Sugg, J. E., Morris, D., Zhang, J., Bhattacharyya, H., King, E. C., & Hopkins, R. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00008 · Cited by 226
McMahon, B. J., Hennessy, T. W., Bensler, J. M., Bruden, D. L., Parkinson, A. J., Morris, J. M., Reasonover, A. L., Hurlburt, D. A., Bruce, M. G., Sacco, F., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-6-200309160-00008 · Cited by 198
Peura, D. A. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)80003-0 · Cited by 163
Cited by
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312288 · Cited by 2,946
Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Atherton, J., Axon, A. T. R., Bazzoli, F., Gensini, G. F., Gisbert, J. P., Graham, D. Y., Rokkas, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302084 · Cited by 2,266
Malfertheiner, P., Megraud, F., O'Morain, C., Bazzoli, F., El-Omar, E., Graham, D., Hunt, R., Rokkas, T., Vakil, N., Kuipers, E. J., et al. (2007) · Gut · doi:10.1136/gut.2006.101634 · Cited by 2,240
Malfertheiner, P., Chan, F. K., & McColl, K. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60938-7 · Cited by 1,488
American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
Chey, W. D., Wong, B. C. Y., & Practice Parameters Committee of the American College of Gastroenterology (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01393.x · Cited by 1,406
Self-citation
Metadata
- Authors
- Saad, R. J., Schoenfeld, P., Kim, H. M., & Chey, W. D.
- Venue
- The American Journal of Gastroenterology
- Published
- 2006-03
- Volume
- 101
- Issue
- 3
- Pages
- 488-496
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W1989413302
- Cited by
- 261
- References
- 19
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent Helicobacter pylori Infection: A Meta-Analysis. CME. https://app.cochat.ai/papers/10.1111/j.1572-0241.2006.00637.x
- The paper
- Saad, R. J., Schoenfeld, P., Kim, H. M., & Chey, W. D. (2006). Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent Helicobacter pylori Infection: A Meta-Analysis. CME. The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2006.00637.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.